HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer

Oncogene

Volumn 33, Issue 40, 2014, Pages 4867-4876

  Lai, C H ^a,c   Park, K S ^a   Lee, D H ^a   Alberobello, A T ^a   Raffeld, M ^a   Pierobon, M ^b   Pin, E ^b   Petricoin, E F ^b   Wang, Y ^a   Giaccone, G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Doxorubicin; Ganetespib; Hsp90 inhibitor; RIP1; SCLC

Indexed keywords

CASPASE 3; DOXORUBICIN; ETOPOSIDE; GANETESPIB; PROTEIN SERINE THREONINE KINASE; SCAFFOLD PROTEIN; SMALL INTERFERING RNA; TANESPIMYCIN; ANTINEOPLASTIC ANTIBIOTIC; HEAT SHOCK PROTEIN 90; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL DEATH; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; MTS ASSAY; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; IC50; LUNG NEOPLASMS; NUDE MOUSE; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG SYNERGISM; G2 PHASE CELL CYCLE CHECKPOINTS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MICE; MICE, NUDE; SMALL CELL LUNG CARCINOMA; TRIAZOLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921712255     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.439     Document Type: Article

References (53)

1. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-1396.
2. Schmittel A. Second-line therapy for small-cell lung cancer. Expert Rev Anticancer Ther 2011;11:631-637.
3. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007;12:1096-1104.
4. Singhal SS, Yadav S, Singhal J, Awasthi YC, Awasthi S. Determinants of differential doxorubicin sensitivity between SCLC and NSCLC. FEBS Lett 2006;580:2258-2264.
5. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
6. Shibakura M, Niiya K, Kiguchi T, Kitajima I, Niiya M, Asaumi N et al. Induction of IL-8 and monoclyte chemoattractant protein-1 by doxorubicin in human small cell lung carcinoma cells. Int J Cancer 2003;103:380-386.
7. Gangadharan C, Thoh M, Manna SK. Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J Cell Biochem 2009;107:203-213.
8. Califano R, Abidin AZ, Peck R, Faivre-Finn C, Lorigan P. Management of small cell lung cancer: recent developments for optimal care. Drugs 2012;72:471-490.
9. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006;31:164-172.
10. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-772.
11. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-410.
12. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007;13:1625-1629.
13. Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem 2000;275:10519-10526.
14. Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, Müller C et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 2012;109:17034-17039.
15. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-1116.
16. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012;11:475-484.
17. Wang Y, Trepel JB, Neckers LM, Giaccone G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 2010;11:1466-1476.
18. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009;9:1479-1492.
19. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ et al. Ganetespib (STA-9090), a non-Geldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012;18:4973-4985.
20. Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs 2012;30:2201-2209.
21. Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA et al. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood 2010;116:4591-4599.
22. Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 2007;3:498-507.
23. Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 2011;6:e18552.
24. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reversephase lysate microarrays. Proc Natl Acad Sci USA 2003;100:14229-14234.
25. Sheehan KM, Gulmann C, Eichler GS, Weinstein JN, Barrett HL, Kay EW et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 2008;27:323-331.
26. Choi HJ, Fukui M, Zhu BT. Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole. PLoS One 2011;6:e24312.
27. Scaffidi C, Volkland J, Blomberg I, Hoffmann I, Krammer PH, Peter ME et al. Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunol 2000;164:1236-1242.
28. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of celldeath proteases in neurodegeneration. Cell Commun Signal 2010;8:31.
29. Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011;471:373-376.
30. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008;105:11778-11783.
31. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha) - induced NF-kappaB activation. J Biol Chem 2008;283:24295-24299.
32. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 2004;6:29-40.
33. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000;60:3940-3946.
34. Robles AI, Wright MH, Gandhi B, Feis SS, Hanigan CL, Wiestner A et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res 2006;12:6547-6556.
35. Sugimoto K, Sasaki M, Isobe Y, Tsutsui M, Suto H, Ando J et al. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene 2008;27:3091-3101.
36. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001;15:1537-1543.
37. Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, Broude EV et al. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Differ 2006;13:1434-1441.
38. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, Morgan GJ et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007;110:2641-2649.
39. Banerji U, Judson I, Workman P. The clinical applications of heat shock protein inhibitors in cancer - present and future. Curr Cancer Drug Targets 2003;3:385-390.
40. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13(Suppl 1):S125-S135.
41. Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell 2009;138:229-232.
42. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG et al. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 2001;276:48921-48929.
43. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291.
44. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-861.
45. Sculier JP, Klastersky J, Libert P, Ravez P, Brohee D, Vandermoten D et al. A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer. Lung Cancer 1990;6:110-118.
46. Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987;71:941-944.
47. Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, Agra Varela Y. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2009;7: CD001990.
48. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-2603.
49. Kotani Y, Satouchi M, Ando M, Nakagawa K, Yamamoto N, Ichinose Y et al. A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509. J Clin Oncol (Meeting Abstracts) 2012;30(suppl):7003.
50. Cook RM, Miller YE, Bunn Jr. PA. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer 1993;17:69-141.
51. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-446.
52. Park KS, Kim DS, Ko C, Lee SJ, Oh SH, Kim SY et al. TNF-alpha mediated NF-kappaB activation is constantly extended by transglutaminase 2. Front Biosci (Elite Ed) 2011;3:341-354.
53. Pierobon M, Vanmeter AJ, Moroni N, Galdi F, Petricoin 3rd EF. Reverse-phase protein microarrays. Methods Mol Biol 2012;823:215-235.